Adaptimmune Therapeutics Plc ADR [ADAP] stock is trading at $0.17, up 15.93%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ADAP shares have gain 151.35% over the last week, with a monthly amount glided 186.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on July 29, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Mizuho downgraded its rating to Neutral on June 26, 2025, and kept the price target unchanged to $0.50. On July 30, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $4 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $3.15 on May 30, 2024. Bryan Garnier initiated its recommendation with a Buy and recommended $3.60 as its price target on March 24, 2023. Guggenheim upgraded its rating to Buy for this stock on January 03, 2023, but kept the price target unchanged to $5. In a note dated November 09, 2022, Mizuho upgraded a Buy rating on this stock but restated the target price of $9.
Adaptimmune Therapeutics Plc ADR [ADAP] stock has fluctuated between $0.04 and $1.03 over the past year. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.17 at the most recent close of the market. An investor can expect a potential return of 1564.71% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] reported sales of 65.66M for the trailing twelve months, which represents a drop of -89.22%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -2.52%, Pretax Profit Margin comes in at -2.52%, and Net Profit Margin reading is -2.61%. To continue investigating profitability, this company’s Return on Assets is posted at -1.3, Equity is 41.03 and Total Capital is -2.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1477 points at the first support level, and at 0.1281 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1903, and for the 2nd resistance point, it is at 0.2133.
Ratios To Look Out For
For context, Adaptimmune Therapeutics Plc ADR’s Current Ratio is 1.52. In addition, the Quick Ratio stands at 1.29 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 0.68.
Transactions by insiders
Recent insider trading involved Wood Gavin, Chief Financial Officer, that happened on Sep 02 ’25 when 96000.0 shares were sold. Chief Financial Officer, Gavin Wood completed a deal on Sep 02 ’25 to buy 16000.0 shares. Meanwhile, Chief Operating Officer Bertrand William C JR sold 0.21 million shares on Aug 28 ’25.
